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Abstract: Locally advanced non-small cell lung cancer (NSCLC) represents approximately one third 
of presentations at diagnosis. Most patients are judged non-surgical due to disease extension, and chemo-
radiotherapy still represents the standard therapeutic option, with unsatisfactory results in terms of overall 
survival (OS) despite advances in staging and radiation therapy planning and delivery. Immunotherapy, 
and in particular immune-checkpoint inhibitors targeting the PD-1/PD-L1 axis, gained wide popularity 
for NSCLC in light of the positive findings of several trials in metastatic disease. Stage III unresectable 
NSCLC is a remarkably interesting setting for the combined use of chemo-radiation and immunotherapy, 
also considering the multiple experimental evidences in favor of a synergistic effect between radiation and 
immune checkpoint inhibitors, with the potential of enhancing immuno-modulating effects and overcoming 
resistance. We here summarized the biological rationale and the initial clinical experiences testing for this 
combination, and we briefly discussed ongoing trials and future options in this field.
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Introduction
According to the tumor node metastases  (TNM) 
international staging system, approximately thirty percent of 
patients affected with non-small cell lung cancer (NSCLC) 
are diagnosed with “locally advanced” disease (1). This 
group includes a wide spectrum of clinical presentations 
with often a considerable tumor burden (T3-T4 and 
N2-N3). Beyond stages III A and B, the latest TNM 
(8th edition) also introduces stage IIIC, which refers 
to a massive parenchymal localization combined with 
contralateral lymph nodes involvement (T3-T4 and N3) (2). 
Most of stage III NSCLC patients are judged as non-
surgical given the disease extension. Despite the absence 
of metastases their prognosis is severe (with differences 
across sub-stages), with 5-year overall survival (OS) rate 
of approximately 20% after concomitant or sequential 
chemo-radiation (3). As in phase 2 trials a progressive 
increase in radiation dose resulted associated to better local-
regional control and OS, Radiation Therapy Oncology 
Group (RTOG) conducted a prospective phase 3 study to 
establish the safety and efficacy of increasing total radiation 
dose with concurrent carboplatin-paclitaxel, comparing 
60 vs. 74 Gy, with negative results (RTOG0617) (4). The 
control arm (60 Gy) of this study reached a median OS of 
28.7 months, a result previously unseen in any historical 
study, now representing a new benchmark for comparison. 
On the front of radiation dose escalation, other groups 
tested the possibility of delivering a stereotactic boost after 
conventional radiation therapy (RT) in order to selectively 
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increase tumor dose, with promising results in terms of 
feasibility and local control without survival benefits, and 
still unconfirmed results by high-quality prospective studies 
(5,6). Although the outcomes after concomitant chemo-
radiation in this setting appear better than before, still not 
all patients are eligible, making this therapeutic choice 
limited to a selected group of generally younger and fit 
patients. Beyond radiation dose escalation, a logical step for 
improving survival for non-surgical stage III patients was 
to investigate for the combination of chemo-radiotherapy 
with targeted agents (gefitinib, erlotinib) and/or anti-
angiogenic therapies (bevacizumab), following the positive 
results obtained for these drugs in stage IV. However, 
these attempts did fail in increasing survival, while adding 
significant toxicity (7). 
A new window of  opportuni ty  emerged  when 
immunotherapy gained exceptional popularity for its high 
efficacy for a heterogeneous group of metastatic solid 
tumors, including NSCLC. The first clinical applications, in 
particular the use of immune checkpoint inhibitors targeting 
the PD-1/PD-L1 axis, produced remarkable results in 
metastatic NSCLC, especially in patients overexpressing 
PD-L1 on cancer cells (8-11). These innovative immune-
modulators were then tested for locally advanced disease in 
pivotal trials, and we here summarize the results obtained so 
far, as well as the ongoing trials and our perspective on the 
future options in this setting.
Rationale for the combination of immunotherapy 
and radiotherapy in NSCLC
Radiotherapy has consistently been shown to activate 
key elements  of  the immune system that  may be 
responsible for resistance to immunotherapy (12-16); 
at the same time, radio(chemo)therapy may synergize 
with immunotherapy and possibly overcome resistance 
and potentiate the pro-immunogenic effects (17,18). As 
shown by several experimental studies, RT may convert 
a poorly immunogenic tumor into an immunogenic one, 
by increasing antigen release, T-cells priming and cross-
priming in lymph nodes, T-cells trafficking to tumor 
site, and increased expression of MHC-class 1 molecules 
(19-21). These effects are partially counterbalanced by 
immunosuppressive effects, one of the most important 
being the enhanced PD-L1 expression on cancer cells, 
that can be neutralized promoting a synergistic effect 
when anti-PD-L1 agents are used in combination with 
RT (22). Targeting the PD-1/PD-L1 axis together with 
RT is seen as one of the most promising strategy for 
several solid tumors, and many trials are ongoing with 
the aim to explore the different possible combinations. 
Meanwhile, recent experimental findings showed that 
the interaction between RT and the immune system is 
far more complex than previously thought, and dose/
fractionation may play a central role for activation, by 
a mechanism involving the STING pathway and type I 
interferon release (23). For NSCLC, the combination of 
immunotherapy and RT might potentially improve local 
control at the treated site as well as distant control, when 
a powerful “abscopal” effect is triggered potentiating 
specific anti-cancer immunity and inducing memory 
effect (19). RT, especially when combined with immune-
modulators, has been shown to broaden the T-cell 
receptor (TCR) repertoire, achieving maximal tumor 
rejection (24). The beneficial effects of the combination 
are expected to be maximal when RT and immune 
checkpoint inhibitors are used concomitantly or in a 
close sequence. Moreover, as shown by the clinical results 
obtained so far (25,26), that will be discussed in details in 
the next paragraph, RT seems to potentiate the effects of 
immunotherapy also when given several months before 
immunotherapy, and this effect was, until now, uniquely 
observed in NSCLC patients (26). For locally advanced 
disease, a maintenance approach with anti-PD-1 inhibitors 
given sequentially seems also to be very effective (25). 
In these clinical trials, RT was used not as “immune-
modulator” but as a radical or palliative treatment at 
conventional doses. In future studies, as pointed out by 
De Ruysscher D in a recent commentary (27), it would 
be possible that RT would be used as a pure trigger of the 
immune system, opening the possibility to irradiate only 
partial tumor volumes, or limited metastatic deposits. 
Radiotherapy and immunotherapy for locally 
advanced NSCLC
The setting of locally advanced NSCLC is remarkably 
interesting for the combination of immunotherapy and 
(chemo)-radiotherapy. The main study investigating 
the efficacy of an anti-PD-1 axis inhibitor in association 
with radio-chemotherapy for locally advanced NSCLC 
was the PACIFIC trial (25). This trial compared the 
PD-L1 inhibitor durvalumab vs. placebo in patients 
with locally advanced, unresectable stage III NSCLC 
who did not progress following concurrent platinum-
based chemo-radiotherapy. It included 713 patients, who 
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were randomized 2:1 to receive durvalumab 10 mg/kg 
every 2 weeks or placebo for up to 12 months. The co-
primary endpoints were progression-free survival (PFS) 
and OS. Patients were stratified according to age, sex, 
and smoking habit (current or former smoker vs. never 
smoked). Durvalumab was given until disease progression, 
other therapy initiation, severe collateral effects, or 
withdrawal of informed consent. The secondary endpoints 
were duration of response, objective response rate, 
percentage of patients alive without disease at 12 and 
18 months, time to death or distant metastasis, quality 
of life, pharmacokinetics and immunogenicity. Median 
PFS resulted significantly higher for patients receiving 
Durvalumab than for patients receiving placebo (16.8 vs. 
5.6 months respectively). The authors pointed out how 
the gain in PFS was achieved independently of PD-L1 
expression (<25% vs. >25%). The median time to death 
or distant metastases was 23.2 months for durvalumab vs. 
14.6 months for placebo, respectively, the objective 
response rate was 28.4% vs. 16%, respectively, and 
the median duration of response at 12 and 18 months 
was 72.8% vs. 56.1% and 46.8%, respectively. Patients 
who received durvalumab had a lower incidence of new 
metastases (20.4% vs. 32.1%) and in particular a lower 
incidence of brain metastases (5.5% vs. 11%). The toxicity 
of the two arms was comparable, with and incidence 
of adverse events of any grade of 96.8% and 94.9% in 
patients receiving durvalumab vs. placebo, respectively. 
Grade 3 or 4 adverse events occurred in 29.9% and 26.1%, 
with 4.4% and 5.6% toxic deaths, respectively. 
Pembrolizumab, an anti-PD-1 agent, demonstrated a 
clear efficacy in advanced NSCLC on phase 1 KEYNOTE 
001 trial (28). PD-L1 expression in at least 50% of tumor 
cells was selected as cutoff. In a secondary analysis of this 
trial (26), the authors evaluated all patients enrolled and 
selected those who received radiotherapy at any time-
point before the administration of the first pembrolizumab 
cycle. The main endpoint of the study was the evaluation 
of the impact of previous radiotherapy on PFS and 
OS, in comparison with patients who did not receive 
radiotherapy. As secondary endpoint, the toxicity profile 
of the combination was also evaluated. The status and 
expression of PD-L1 were determined and patients 
with a membranous PD-L1 staining at least 1% were 
considered positive. Pembrolizumab administration 
schedule was 2 or 10 mg/kg every 3 weeks or 10 mg/kg 
every 2 weeks until progression of disease, important 
toxicity or withdrawal of informed consent. Radiotherapy 
was delivered on thoracic and extra-thoracic sites, mostly 
as palliative treatment. Of the 97 patients analyzed, 
42 previously received any RT, 38 extracranial and 
24 thoracic RT (43%, 39% and 25% respectively) with 
a median time of administration of 9.5 months prior to 
pembrolizumab. With a median follow-up of 32.5 months 
for surviving patients, there were 31 progressions in 
the group of patients undergoing previous radiotherapy 
and 49 in the group of patients who did not receive it. 
The combination of radiotherapy and pembrolizumab 
obtained a significantly longer PFS (4.4 and 2.1 months 
respectively). Patients who received prior extracranial 
radiat ion had a  better  PFS (6.3 and 2.0 months, 
respectively). Patients treated with RT also had better 
OS: the median survival of the first group was 10.5 vs. 
5.3 months, and 6-month OS was 73% vs. 45%, respectively. 
Again, patients who received a previous extracranial RT had 
a better OS (11.6 vs. 5.3 months, respectively). Forty-four 
of 97 patients had grade 3 or greater pulmonary toxicity, 
without difference among RT vs. non-RT patients. A 
separate analysis showed that, as far as the side effects were 
closely related to treatment, 3 patients (13%) of the group 
who received prior RT compared to 1% of patients who 
did not receive it developed pulmonary toxicity (17). The 
combined results of these two trials were favorable in terms 
of the potential implementation of a chemo-radiotherapy 
plus immunotherapy approach with anti PD-L1 and PD-1 
inhibitors for both locally advanced and stage IV NSCLC. 
These results are in line with most of the preclinical 
evidence suggesting that there is window of opportunity 
for improving tumor control when using radiation and 
differential immunotherapy strategies. However, the 
exact mechanism underlying these findings in NSCLC is 
still unknown, and many clinical questions remain to be 
answered before a wide application in clinical practice, 
especially the right group of patients, exact sequence of RT-
IT, PD-L1 expression levels.
Tecemotide (L-BLP25) was conceived as an anti-
tumor vaccine inducing a specific immune response 
against MUC-1, a glycoprotein overexpressed and 
unnaturally glycosylated in many tumors, including 
NSCLC (29,30). The aberrant protein stimulates cell 
proliferation, modifies cell adhesion, and promotes 
metastases. Tecemotide, once internalized by antigen 
presenting cells (APCs), is able to promote a T cell-
mediated response against MUC-1 expressing tumors (31). 
In the START study, a randomized, international double- 
blind phase III trial, the authors enrolled 1,513 NSCLC 
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Table 1 Ongoing trials integrating immunotherapy in the therapeutic management of locally advanced NSCLC
Study Number Phase Immunotherapy Institution
Estimated 
completion date
Cisplatin and etoposide plus radiation 
followed by nivolumab/placebo for locally 
advanced NSCLC (RTOG 3505)
NCT02768558 III Anti-PD-1, adjuvant RTOG 
Foundation
October 2024
Nivolumab combination with standard 
first-line chemotherapy and radiotherapy 
in locally advanced stage IIIA/B non-small 
cell lung carcinoma (NICOLAS)







Pembrolizumab in combination with 
radiotherapy in locally advanced non-small 
cell lung cancer (NSCLC) (PARIS)









patients with inoperable stage III NSCLC, in objective 
clinical response or stable disease after definitive chemo-
radiation. Patients were randomized to receive adjuvant 
tecemotide for 8 weekly cycles or placebo at a ratio 
of 2:1. OS was not significantly different between the 
two groups (25.6 vs. 22.3 months, respectively) even 
if, in a secondary analysis, patients who underwent 
concomitant chemo-radiotherapy had a better OS (30.8 vs. 
20.6 months, respectively) (32). The INSPIRE study 
aimed at investigating the eff icacy of tecemotide 
associated with best  supportive care (BSC) as an 
alternative to placebo plus BSC after chemo-radiotherapy 
in stage III NSCLC East-Asian patients. Patients were 
randomized to receive 8 weekly doses of tecemotide plus 
maintenance for further 6 weeks, or placebo. The main 
endpoint of the study was OS, but unfortunately the 
study was prematurely closed (33). To our knowledge, 
at the time of writing no other reports were available on 
the combination of immunotherapy and radio (chemo) 
therapy for stage III NSCLC.
Ongoing studies and future perspectives
Radiation therapy for locally advanced NSCLC has 
evolved over several decades with the aim of developing 
specific protocols optimized to maximize local tumor 
control through radiation dose escalation, or the 
combination with chemotherapy. Many attempts in 
prolonging OS did fail, and at the same time standard 
chemo-radiation (platinum doublets and 60 Gy/6 weeks 
thoracic RT) reached unprecedented results in terms 
of median OS time in recent randomized comparisons, 
probably as a consequence of the better initial staging 
through the wide use of PET-CT, lower toxicity of RT 
through the use of advanced planning techniques, better 
quality of life, better supportive care. Despite these 
positive findings, still most of the patients relapse and 
die due to disease progression. The growing enthusiasm 
for immune-oncology and its possible applications in 
radiation oncology led to a tremendous expansion of pre-
clinical and clinical studies testing various combinations of 
immunotherapeutic agents and radiation. We summarized 
the results obtained so far by combining chemo-radiation 
and immune checkpoint inhibitors in pivotal trials that 
explored this strategy for stage III NSCLC, with truly 
encouraging results. However, given the complexity of 
the field and the paucity of data, we still need to wait for 
other experimental findings prior to confirm the efficacy 
of this approach. Particularly, we need to revisit our 
current understanding of the radiation/immune system 
interactions in order to develop more tailored strategies 
in terms of dose/fractionation, timing, target volumes and 
drugs choice, in light of the recent advances in knowledge 
coming from translational studies.
In Table 1 we present the ongoing studies retrieved by 
Clinicaltrials.gov, November 2017. As we can see from 
the Table, many different options are under investigation 
by several researchers across USA and Europe. In almost 
all trials, the target is the PD-1/PD-L1 axis, with the 
exception of a combination of anti-CTLA-4 and anti-
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PD-L1 agents. Multiple sequences are being tested: a 
predominance for the consolidation/adjuvant/maintenance 
setting is evident, however with many studies also integrating 
immunotherapy at the beginning of chemo-radiation. The 
latter schedule should be one of the most efficient way to 
harness at maximum the synergistic effects of chemo-radiation 
and immunotherapy in terms of boosting the immune-
stimulating effects, particularly when using anti-PD-L1 
agents, given that PD-L1 enhanced expression during RT 
may be one of the main causes of radioresistance. A particular 
attention should also be paid to those trials introducing anti-
PD-1 agents before chemo-radiation, as neo-adjuvant: this 
innovative approach could be promising, by integrating radio-
chemotherapy in a tumor micro-environment already modified 
by immunomodulators, and with a subsequent consolidation 
phase. When using anti-PD-L1 agents in this setting, PD-
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